This is a working overview of telomerase, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-29. Anything still debated is marked as such rather than presented as settled.
The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.
Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
In its supplied form epitalon is a white to off-white powder, usually lyophilized and often hygroscopic. It dissolves readily in water and in aqueous buffers, and it is commonly handled as the acetate or trifluoroacetate salt to improve stability during purification and drying. The amide backbone is labile in aqueous media, so solutions are less durable than the dry solid. Handling notes in the chemical literature therefore emphasize keeping the powder dry, cool and shielded from light until it is dissolved.
Epitalon is a synthetic tetrapeptide whose sequence is alanine-glutamate-aspartate-glycine, written in single-letter code as AEDG. The four residues are joined by three peptide bonds, giving a linear backbone with no branching and no disulfide bridges. Its calculated molecular mass for the free form is approximately 390.3 daltons, a figure that rises when the compound is supplied as an acetate or trifluoroacetate salt. Because the chain is short, the molecule is defined entirely by its residue order rather than by any folded three-dimensional structure.
The compound is described in the literature as a derivative of epithalamin, a preparation obtained from bovine pineal tissue. Work on this peptide family was carried out mainly by a research group in Saint Petersburg beginning in the 1980s, and the substance was later registered for clinical use in Russia under the name Epitalon. Outside that region it is generally treated as a research chemical rather than an approved medicine. Statements about its biological activity rest on a relatively small number of studies, and independent replication remains limited.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Ala-Glu-Asp-Gly | Often abbreviated AEDG in research literature |
| Common synonyms | Epithalon, epitalon, AEDG | Spelling variants refer to the same tetrapeptide |
| Molecular formula | C14H22N4O9 | Theoretical monoisotopic mass near 390.35 Da |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Freely soluble in water | Hydrophilic peptide; dissolves in aqueous buffer |
C6H4(C(O)NH2)CO2Na + HOCl → C6H4NH2CO2H + NaCl + CO2 A related method involves treating phthalimide with sodium hypobromite in aqueous sodium hydroxide, followed by neutralization. In the era when indigo dye was obtained from plants, it was degraded to give anthranilic acid. Anthranilic acid was first obtained by base-induced degradation of indigo.
Powder cocaine (cocaine hydrochloride) must be heated to a high temperature to be smoked (about 197 °C), and considerable decomposition/burning occurs at these high temperatures. This effectively destroys some of the cocaine and yields a sharp, acrid, and foul-tasting smoke. Cocaine base/crack can be smoked because it vaporizes with little or no decomposition at 98 °C (208 °F).
== Coronavirus response == Coronaviruses evade innate immunity during the first ten days of viral infection. In the early stages of infection, SARS-CoV-2 induces an even lower interferon type I (IFN-I) response than SARS-CoV, which itself is a weak IFN-I inducer in human cells. SARS-CoV-2 limits the IFN-III response as well. Reduced numbers of plasmacytoid dendritic cells with age is associated with increased COVID-19 severity, possibly because these cells are substantial interferon producers. Ten percent of patients with life-threatening COVID-19 have autoantibodies against type I interferon. Delayed IFN-I response contributes to the pathogenic inflammation (cytokine storm) seen in later stages of COVID-19 disease. Application of IFN-I prior to (or in the very early stages of) viral infection can be protective, which should be validated in randomized clinical trials. With pegylated IFN lambda, the relative risk for hospitalization with the Omicron strains is reduced by about 80 %.
== History == 3-HO-PCP was mentioned by a chemist under the pseudonym "John Q. Beagle" in 1999 in a post on The Hive. The psychoactive effects of 3-HO-PCP have been described by Bluelight users even before its availability as a research chemical in 2009.
=== Schedule === The WHO recommends one or two doses with the initial dose given at 12 to 18 months of age. The second dose, if given, should occur at least one to three months later. The second dose, if given, provides the additional benefit of improved protection against all varicella. This vaccine is a shot given subcutaneously (under the skin). It is recommended for all children under 13 and for everyone 13 or older who has never had chickenpox. In the United States, two doses are recommended by the CDC. For a routine vaccination, the first dose is administered at 12 to 15 months of age and the second dose at age 4–6 years. However, the second dose can be given as early as 3 months after the first dose. If an individual misses the timing for the routine vaccination, the individual is eligible to receive a catch-up vaccination. For a catch-up vaccination, individuals between 7 and 12 years old should receive a two-dose series 3 months apart (a minimum interval of 4 weeks). For individuals 13–18 years old, the catch-up vaccination should be given 4 to 8 weeks apart (a minimum interval of 4 weeks). The varicella vaccine did not become widely available in the United States until 1995. In the United Kingdom, the varicella vaccine has been added in 2026 to the routine children vaccination, combined with the MMR vaccine, at ages 12 and 18 months, starting with children born in 2025, with the possibility of catchup for children born in 2022, 2023 and 2024.
Sources: en.wikipedia.org
{\displaystyle {\underset {{\text{copper(II) sulfate}} \atop {\text{pentahydrate}}}{{\ce {CuSO4*5H2O}}}}\longrightarrow {\underset {{\text{anhydrous}} \atop {\text{copper(II) sulfate}}}{{\ce {CuSO4}}}}+{\ce {5 H2O}}}
Between 1979 and 1980, the pace of infiltration had accelerated so greatly that the SADF was forced to mobilise its reserves and deploy another 8,000 troops to South West Africa. The deeper South African raids struck into Angola, the more the war spread, and by mid-1980 the fighting had extended to a much larger geographic area than before. Operation Sceptic, then the largest combined arms offensive undertaken by South Africa since World War II, was launched in June against a PLAN base at Chifufua, over a hundred and eighty kilometres inside Angola. Chifufua, codenamed Objective Smokeshell, was divided into a dozen well fortified complexes ringed with trenches, defensive bunkers, and anti-aircraft positions. The SADF killed over 200 insurgents and captured several hundred tonnes of PLAN munitions and weaponry at the cost of 17 dead. Operation Protea was mounted on an even larger scale and inflicted heavier PLAN casualties; unlike Sceptic, it was to involve significant FAPLA losses as well as the seizure of substantial amounts of Angolan military hardware and supplies. Protea was planned when the SADF first became aware of PLAN's evolving conventional capabilities in August 1981. Its targets were suspected PLAN bases sited outside major FAPLA installations at Ondjiva and Xangongo. Attacking either settlement was considered especially risky due to the presence of Soviet advisers and a comprehensive local FAPLA air defence network.
non-coding DNA (ncDNA) Any segment of DNA that does not encode a sequence that may ultimately be transcribed and translated into a protein. In most organisms, only a small fraction of the genome consists of protein-coding DNA, though the proportion varies greatly between species. Some non-coding DNA may still be transcribed into functional non-coding RNA (as with transfer RNAs) or may serve important developmental or regulatory purposes; other regions (as with so-called "junk DNA") appear to have no known biological function.
Under normal circumstances in humans, growth hormone (GH) is released in a pulsatile fashion from cells known as somatotrophs in the anterior pituitary gland. These pulses of GH are regulated by cells in the hypothalamus, via the release of growth hormone-releasing hormone (GHRH) into the hypothalamohypophysial system when stimulated by insulin, ghrelin, glucagon, arginine, deep sleep, exercise, fasting, sex hormone release during puberty, and a host of other factors. GH release is inhibited by somatostatin (GHIH), IGF-1, hyperglycemia, and glucocorticoids. Once released, the GH molecules travel through the bloodstream and eventually bind to GH receptors on the surface of cells composing bodily organs and tissues. One major site of action for GH is in the liver, where it stimulates gluconeogenesis and the release of IGF-1 through the JAK-STAT signaling pathway. IGF-1 promotes growth in a variety of tissues throughout the body, especially bone mineralization, and provides negative feedback on GH release. GH results in increased muscle mass, lipolysis, and protein synthesis. Obesity and increased adipose tissue, especially visceral fat, results in reduced GH secretion. There is a natural age-related decline in the GHRH-stimulated release of GH.
Sources: en.wikipedia.org
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine–glutamate–aspartate–glycine, also written AEDG. It was developed in Russian gerontology research and is studied for proposed effects on telomerase, melatonin regulation, and neuroendocrine function. It is not an approved pharmaceutical in the United States or the European Union.
No. Epithalamin is a peptide-rich extract prepared from bovine pineal glands, while epitalon is a short synthetic peptide designed as a defined analogue of it. The synthetic version was intended to provide a reproducible molecule with some of the same proposed biological activity.
Telomere elongation and telomerase activation have been reported in cultured human somatic cells, but evidence from living human subjects is limited and has not been independently confirmed at scale. Reported findings come largely from small studies with differing designs, so the question remains open rather than settled.
The peptide contains four residues in the order alanine, glutamate, aspartate and glycine, abbreviated AEDG. The chain is linear and held together by three peptide bonds. Its calculated mass for the uncharged free form is about 390.3 daltons.